These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 26286831)
1. A new application of plant virus nanoparticles as drug delivery in breast cancer. Esfandiari N; Arzanani MK; Soleimani M; Kohi-Habibi M; Svendsen WE Tumour Biol; 2016 Jan; 37(1):1229-36. PubMed ID: 26286831 [TBL] [Abstract][Full Text] [Related]
2. Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines. Hajighasemlou S; Alebouyeh M; Rastegar H; Manzari MT; Mirmoghtadaei M; Moayedi B; Ahmadzadeh M; Parvizpour F; Johari B; Naeini MM; Farajollahi MM Asian Pac J Cancer Prev; 2015; 16(14):5977-81. PubMed ID: 26320483 [TBL] [Abstract][Full Text] [Related]
3. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells. Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314 [TBL] [Abstract][Full Text] [Related]
4. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells. Varshosaz J; Davoudi MA; Rasoul-Amini S J Liposome Res; 2018 Dec; 28(4):285-295. PubMed ID: 28826287 [TBL] [Abstract][Full Text] [Related]
5. Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery. Zhou Z; Badkas A; Stevenson M; Lee JY; Leung YK Int J Pharm; 2015 Jun; 487(1-2):81-90. PubMed ID: 25865568 [TBL] [Abstract][Full Text] [Related]
6. Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. Abedin MR; Powers K; Aiardo R; Barua D; Barua S Sci Rep; 2021 Apr; 11(1):7347. PubMed ID: 33795712 [TBL] [Abstract][Full Text] [Related]
7. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. Vivek R; Thangam R; NipunBabu V; Rejeeth C; Sivasubramanian S; Gunasekaran P; Muthuchelian K; Kannan S ACS Appl Mater Interfaces; 2014 May; 6(9):6469-80. PubMed ID: 24780315 [TBL] [Abstract][Full Text] [Related]
8. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study. Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638 [TBL] [Abstract][Full Text] [Related]
9. Chemical addressability of potato virus X for its applications in bio/nanotechnology. Le DHT; Hu H; Commandeur U; Steinmetz NF J Struct Biol; 2017 Dec; 200(3):360-368. PubMed ID: 28647539 [TBL] [Abstract][Full Text] [Related]
10. Comparison of three different conjugation strategies in the construction of herceptin-bearing paclitaxel-loaded nanoparticles. Yu K; Zhou Y; Li Y; Sun X; Sun F; Wang X; Mu H; Li J; Liu X; Teng L; Li Y Biomater Sci; 2016 Aug; 4(8):1219-32. PubMed ID: 27367271 [TBL] [Abstract][Full Text] [Related]
11. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. Mi Y; Zhao J; Feng SS J Control Release; 2013 Aug; 169(3):185-92. PubMed ID: 23403395 [TBL] [Abstract][Full Text] [Related]
12. Potato virus X, a filamentous plant viral nanoparticle for doxorubicin delivery in cancer therapy. Le DH; Lee KL; Shukla S; Commandeur U; Steinmetz NF Nanoscale; 2017 Feb; 9(6):2348-2357. PubMed ID: 28144662 [TBL] [Abstract][Full Text] [Related]
13. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472 [TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery. Huang R; Sun Y; Zhang XY; Sun BW; Wang QC; Zhu J Biomed Pharmacother; 2015 Jul; 73():116-22. PubMed ID: 26211591 [TBL] [Abstract][Full Text] [Related]
15. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer. Chattopadhyay N; Cai Z; Pignol JP; Keller B; Lechtman E; Bendayan R; Reilly RM Mol Pharm; 2010 Dec; 7(6):2194-206. PubMed ID: 20973534 [TBL] [Abstract][Full Text] [Related]
16. Presentation and Delivery of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand via Elongated Plant Viral Nanoparticle Enhances Antitumor Efficacy. Le DHT; Commandeur U; Steinmetz NF ACS Nano; 2019 Feb; 13(2):2501-2510. PubMed ID: 30668110 [TBL] [Abstract][Full Text] [Related]
17. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. Chiu SJ; Ueno NT; Lee RJ J Control Release; 2004 Jun; 97(2):357-69. PubMed ID: 15196762 [TBL] [Abstract][Full Text] [Related]
18. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347 [TBL] [Abstract][Full Text] [Related]
19. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Sun B; Ranganathan B; Feng SS Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985 [TBL] [Abstract][Full Text] [Related]
20. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells. Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]